Arbutus Biopharma Corporation (NASDAQ:ABUS) Q2 2022 Earnings Conference Call August 4, 2022 8:45 AM ET

Company Participants

Lisa Caperelli - Vice President of Investor Relations

Bill Collier - President & Chief Executive Officer

David Hastings - Chief Financial Officer

Gaston Picchio - Chief Development Officer

Mike Sofia - Chief Scientific Officer

Conference Call Participants

Roy Buchanan - JMP Securities

Dennis Ding - Jefferies

Brian Skorney - Baird

Keay Nakae - Chardan

Thomas Yip - H.C. Wainwright

Operator

Good morning. My name is Abby and I will be your conference operator today. At this time, I would like to welcome everyone to the Arbutus Biopharma 2022 Second Quarter Financial Results and Corporate Update. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Thank you.

Ms. Lisa Caperelli, Vice President of Investor Relations, you may begin your conference.

Lisa Caperelli

Thank you, Abby. Good morning, everyone, and thank you for joining our second quarter 2022 financial results and corporate update call. Joining me today from the Arbutus executive team are Bill Collier, President and Chief Executive Officer; David Hastings, Chief Financial Officer; Dr. Gaston Picchio, Chief Development Officer; and Dr. Mike Sofia, Chief Scientific Officer.

Bill will begin with a corporate update, followed by Dave Hastings who will provide a review of the company's second quarter 2022 financial results. After opening remarks, we will open the call up for Q&A. Gaston Picchio and Mike Sofia will be available to address clinical and development-related questions.

Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements, which are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in our most recent annual report on 10-K, quarterly report on Form 10-Q to be filed later today and from time to time in our other documents filed with the SEC.

With that, I'll turn the call over to Bill Collier. Bill?

Bill Collier

Thank you, Lisa, and good morning, everyone. Thank you for joining us today. We appreciate your continued interest and support for Arbutus Biopharma.

Now with the first half of this year behind us, we've made significant progress in advancing our preclinical and clinical programs in support of our mission to develop a functional cure for hepatitis B virus and to treat COVID-19 and future coronavirus outbreaks.